ABVC Biopharma, Inc. (ABVC)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.97
- As of
Kresmion compiles this page from ABVC's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
ABVC BIOPHARMA, INC. (ABVC): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-02.
See the full ABVC dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ABVC on one page. Preview it with sample data, then open it live with a free account.
Preview the ABVC dossierActive events for ABVC
- high13F: large reduction
CITADEL ADVISORS LLC cut 79% of ABVC (2026Q2)
- mediumEarnings below estimates
Q1-2023: Missed consensus by 17.6% - EPS $-0.6 vs $-0.51 estimate
- mediumEarnings below estimates
Missed consensus by 17.6% - EPS $-0.6 vs $-0.51 estimate
- mediumEarnings below estimates
Q2-2023: Missed consensus by 1011.1% - EPS $-0.68 vs $-0.0612 estimate
FREE, NO ACCOUNT
Every event on ABVC, as it fires
New filings, 13F moves and cross asset events on ABVC land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
ABVC positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| CITADEL ADVISORS LLC FundCUSIP 00091F304 · 2026Q2 | $114K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ABVC
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
Going concern statement
ABVC's 10-Q filed Aug 12, 2026 states:
All of these factors raise substantial doubt about the ability of the Company to continue as a going concern.
Read the 10-Q on SEC EDGAR Every company with a going concern statement
More data on ABVC
ABVC against its peers
ABVC's operating margin of -1403.3% ranks in the 42nd percentile of 5 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.
| Metric | ABVC | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 509589 USD | 1.3M USD | 50 | 8 |
| Gross margin | 99.9% | n/a | n/a | 1 |
| Operating margin | -1403.3% | -706.2% | 42 | 5 |
| Net margin | -1551.9% | -633.9% | 21 | 6 |
| Return on equity | -71.2% | -89.5% | 59 | 15 |
Peers (19): BYSI, CVM, ALGS, RNAZ, MGX, CELU, NXTC, AARD, ACET, EDSA, IMMP, GNTA, PVCT, HEPA, BRNS, FLNA, CRVO, QNCX, LITS. Left out: TTIPF (no annual filing), PLRZ (no annual filing), EVAX (no annual filing), MDNAF (no annual filing), SEOVF (no annual filing), RLFTY (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (ABVC: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in ABVC on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on ABVC in the last 180 days.
Upstream: SEC EDGAR filings for ABVC
Kresmion, "ABVC BIOPHARMA, INC. (ABVC) institutional holdings and SEC filings", data as of 2026-11-02, https://kresmion.com/research/ABVC. Upstream data: SEC EDGAR filings for ABVC.
Link to this data (HTML):
<a href="https://kresmion.com/research/ABVC">ABVC BIOPHARMA, INC. (ABVC) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow ABVC on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to ABVC for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.